Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 37%
Hold 26%
Sell 5%
Strong Sell 0%

Bulls say

Edwards Lifesciences is experiencing positive momentum in its financial performance, with operating margins expanding by 100 basis points, supported by foreign exchange benefits, and aligning with the company's strategic growth targets. The firm anticipates approximately 10% average annual sales growth, excluding foreign exchange impacts, driven by an increasing contribution from its structural heart therapies and a recovery in TAVR procedure volumes due to enhanced hospital capacities and favorable clinical data. Additionally, the growth of the Cordella heart failure monitoring device, alongside reaffirmed 2025 sales guidance, indicates a promising outlook for sustained revenue growth and EPS leverage as the company continues to strengthen its market position.

Bears say

The financial outlook for Edwards Lifesciences appears negative due to several key factors that may hinder growth. Firstly, there are concerns regarding the TAVR business growth outlook, which may be lower than investor expectations, as well as a potentially smaller total addressable market than currently projected. Additionally, the company's innovation pipeline for tricuspid and mitral valve repair products may experience delays, and the challenging global regulatory and reimbursement environment could further impede the adoption of new technologies.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $93.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $93.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.